ライフサイエンスコーパス: beta-lactamase

1 s linked to catalytic activity of the CTX-M9 beta lactamase.

2 on did not inhibit unfolding of the inserted beta-lactamase.

3 tes in an important antibiotic target--TEM-1 beta-lactamase.

4 ed at single sites randomly throughout TEM-1 beta-lactamase.

5 oducing an AmpC and 11 coproducing a metallo-beta-lactamase.

6 ng detection of the beta-lactam, of the AmpC beta-lactamase.

7 ssion for the beta-lactam resistance enzyme, beta-lactamase.

8 (5/29) of which expressed extended-spectrum beta-lactamase.

9 ancestor was unlikely to have been a metallo-beta-lactamase.

10 ity for BlaC over TEM-1 Bla, the most common beta-lactamase.

11 lla pneumoniae carbapenemase (KPC-2) class A beta-lactamase.

12 with isolates coproducing an AmpC or metallo-beta-lactamase.

13 90.1% of isolates that coproduced a metallo-beta-lactamase.

14 mases (ESBLs), AmpCs, K1, and broad-spectrum beta-lactamases.

15 ucleophilic serine enzymes, including serine-beta-lactamases.

16 lo-beta-lactamases such as New Delhi metallo-beta-lactamases.

17 carbapenemase activity of the GES family of beta-lactamases.

18 eumoniae carbapenemases (KPC) and additional beta-lactamases.

19 e sensitive detection of clinically-relevant beta-lactamases.

20 an be substituted in the mechanism of serine beta-lactamases.

21 modeling into the active sites of key serine beta-lactamases.

22 chment of resident soil bacteria that harbor beta-lactamases.

23 ded-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

24 overed inhibitors of serine and some metallo beta-lactamases.

25 d resistance, specifically New Delhi metallo-beta-lactamase-1 (NDM-1).

26 esistant E. coli harboring New Delhi metallo-beta-lactamase-1.

27 ess effects of all single mutations in TEM-1 beta-lactamase (4,997 variants) under selection for the

28 pneumoniae carbapenemase (56.1%), 54 metallo-beta-lactamase (40.9%), and four both (3.0%).

29 at SrgE is a T3SS effector by two methods, a beta-lactamase activity assay and a split green fluoresc

30 Metallo-beta-lactamase activity is thought to be polyphyletic, h

31 nts of the TEM-1, TEM-17, TEM-19, and TEM-15 beta-lactamase alleles, which constitute an adaptive pat

32 ytoplasmic events that lead to expression of beta-lactamase, an antibiotic-resistance determinant.

33 S and R164S, two adaptive mutations in TEM-1 beta-lactamase--an enzyme that endows antibiotics resist

34 ei were all ST106, and encoded for blaACT-15 beta-lactamase and fosfomycin resistance (fosA).

35 SpyTag was fused at the N terminus of beta-lactamase and SpyCatcher at the C terminus so that

36 Beta-lactamase and tetracycline resistance genes were th

37 from Klebsiella pneumoniae that includes two beta-lactamase and two aminoglycoside resistance genes.

38 he emergence and spread of extended-spectrum beta-lactamases and carbapenemases among common bacteria

39 onocyclic beta-lactams are stable to metallo-beta-lactamases and have excellent P. aeruginosa activit

40 inhibit clinically relevant class A, C and D beta-lactamases and penicillin-binding proteins, resulti

41 determinants of beta-lactam resistance (e.g. beta-lactamase) and redox potential in Mtb.

42 hia coli (ESBL) (producing extended spectrum beta-lactamases) and Morganella morganii.

43 hyperproducers), K1, other limited-spectrum beta-lactamases, and porin and efflux mutants.

44 s effective against both serine- and metallo-beta-lactamases, and which could also have antimicrobial

45 beta-Lactamases are bacterial enzymes that hydrolyze bet

46 beta-Lactamases are enzymes that confer resistance to be

47 CTX-M beta-lactamases are one of the fastest growing extended-

48 the active sites of DD-peptidases and serine beta-lactamases are very similar.

49 gus Aspergillus niger, and the TEM-family of beta-lactamase associated with antibiotic resistance.

50 nt ribosomal protection proteins and Class A beta-lactamases being the most widely distributed resist

51 promised by resistance, which is provided by beta-lactamases belonging to both metallo (MBL)- and ser

52 The beta-Lactamase (BL) enzyme family is an important class

53 Herein, we report TEM-1 beta-lactamase (bla) as a single-protein reporter for hy

54 as modified to encode toxin with an in-frame beta-lactamase (Bla) fusion.

55 In PRIMERS I, the 4 RMD platforms detected beta-lactamase (bla) genes and identified susceptibility

56 and were based on the absence or presence of beta-lactamase (bla) NDM, VIM, IMP, KPC, and OXA carbape

57 and were based on the absence or presence of beta-lactamase (bla) NDM, VIM, IMP, KPC, and OXA carbape

58 signal with a second antigen fused to TEM-1 beta-lactamase (Bla).

59 for escaping to hydrolysis by broad-spectrum beta-lactamase BlaC.

60 uberculosis (Mtb) expresses a broad-spectrum beta-lactamase (BlaC) that mediates resistance to one of

61 beta-Lactamases (BLs) able to hydrolyze beta-lactam anti

62 Production of beta-lactamases (BLs) is the most widespread resistance

63 m and a bicyclic boronate inhibit L2 (serine beta-lactamase) but not L1 (metallo beta-lactamase) from

64 n) shows stability to most extended spectrum beta-lactamases, but is considered inactive against Pseu

65 For example, the secretion of beta-lactamase by individual bacteria provides passive r

66 both nucleophilic serine and zinc-dependent beta-lactamases by a mechanism involving mimicking of th

67 is it then that the active site of a serine beta-lactamase can catalyze hydrolysis of a beta-lactam

68 r to most class A enzymes, most of the CTX-M beta-lactamases can be inhibited by the clinical inhibit

69 s with the emphasis on the identification of beta-lactamases (carbapenemases OXA-48 and KPC in partic

70 Metallo-beta-lactamases catalyze the hydrolysis of most beta-lac

71 f the ligand binding domain (ER-bla; ERalpha beta-lactamase cell line), in a quantitative high-throug

72 acid by the polyketide synthase ClaG and the beta-lactamase ClaF.

73 our FunFHMMer method can separate the known beta-lactamase classes and identify those positions like

74 Extended-spectrum beta-lactamase colonization was defined by the isolation

75 eftazidime/avibactam are 2 novel beta-lactam/beta-lactamase combination antibiotics.

76 sensitive and specific for the detection of beta-lactamase compared to the blaZ PCR results, whereas

77 TEM beta-lactamase confers bacteria with resistance to many

78 Here we report an artificial metallo-beta-lactamase, constructed via the self-assembly of a s

79 ound genes that encode the extended-spectrum beta-lactamases CTX-M-2, CTX-M-14, and CTX-M-15.

80 ized by screening against nr, SEED, ARDB and beta-lactamase databases.

81 The catalytic efficiency of class D beta-lactamases depends critically on an unusual carboxy

82 resolution X-ray crystal structures of CTX-M beta-lactamase, directly visualizing protonation state c

83 rotein containing a highly conserved metallo-beta-lactamase domain, within which our swip-10 mutation

84 structed a sample of 98 MRCAs of the metallo-beta-lactamases, each based on a different tree in a boo

85 rst product complexes for a wild-type serine beta-lactamase, elucidating the product release mechanis

86 beta-Lactamases enable resistance to almost all beta-lac

87 isms were KPC (K. pneumoniae carbapenemases) beta-lactamases encoded by blaKPC2, blaKPC3, and blaKPC4

88 ay was performed on all isolates to identify beta-lactamase-encoding genes.

89 J, a member of the widely occurring metallo-beta-lactamase enzyme family.

90 actam antibiotics can be mediated by metallo-beta-lactamase enzymes (MBLs).

91 Through experiments using recombinant beta-lactamase enzymes and live bacterial species, these

92 Results from drug sensitivity studies with beta-lactamase enzymes are presented, as well as a struc

93 Point mutations to beta-lactamase enzymes can greatly alter the level of re

94 3 in the catalytic mechanism of class A type beta-lactamase enzymes is still not well understood afte

95 Bacteria use metallo-beta-lactamase enzymes to hydrolyse lactam rings found i

96 equence homology with beta-lactamase/metallo-beta-lactamases (enzymes that provide resistance to a ra

97 eta-lactams is achieved by the production of beta-lactamases, enzymes that catalyze beta-lactam hydro

98 he rapid rise in the number and diversity of beta-lactamases, enzymes that inactivate beta-lactams, a

99 Timely identification of extended-spectrum beta-lactamase (ESBL) bacteremia can improve clinical ou

100 (PTZ) for the treatment of extended-spectrum beta-lactamase (ESBL) bacteremia is controversial.

101 assay was performed on 56 extended-spectrum-beta-lactamase (ESBL) E. coli isolates collected during

102 one of the fastest growing extended-spectrum beta-lactamase (ESBL) families found in Escherichia coli

103 such as strains harboring extended-spectrum beta-lactamase (ESBL) genes, frequently use selective cu

104 la Enterobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose

105 However, the rise of extended spectrum beta-lactamase (ESBL) producing bacteria has limited the

106 g of clinical isolates for extended-spectrum beta-lactamase (ESBL) production (screen plus phenotypic

107 ovar Typhi isolate showing extended spectrum beta-lactamase (ESBL) production in the Democratic Repub

108 h an ertapenem-susceptible extended-spectrum-beta-lactamase (ESBL)-positive phenotype were assessed f

109 s provided pivotal data on extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and C

110 jority of studies reported extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and M

111 Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae gener

112 Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae prese

113 Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, and

114 omonas aeruginosa and most extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.

115 y uncharacterized clinical extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and K.

116 ised CLSI breakpoints, for extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Kle

117 Importance: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are hig

118 Extended spectrum beta-lactamase (ESBL)-producing gram-negative bacilli ar

119 factor for infections with extended-spectrum beta-lactamase (ESBL)-producing organisms.

120 se in infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens is recognized

121 One unreported case of extended-spectrum-beta-lactamase (ESBL)-producing Salmonella enterica sero

122 fection (UTI) caused by an extended-spectrum beta-lactamase (ESBL)-producing, multidrug-resistant ST1

123 production of the CTX-M-15 extended spectrum beta-lactamase (ESBL).

124 inolone resistance (PMQR), extended-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

125 es, respectively, produced extended-spectrum beta-lactamases (ESBL).

126 ical laboratories test for extended-spectrum beta-lactamases (ESBLs) for epidemiological and infectio

127 ance and the occurrence of extended-spectrum beta-lactamases (ESBLs) modulated by farming and manager

128 tion of the genes encoding extended spectrum beta-lactamases (ESBLs) via conjugative plasmids is faci

129 Extended-spectrum beta-lactamases (ESBLs) were reported for 11.0% of Esche

130 50 isolates that produced extended-spectrum beta-lactamases (ESBLs), AmpCs (including hyperproducers

131 n mutants and producers of extended-spectrum beta-lactamases (ESBLs), AmpCs, K1, and broad-spectrum b

132 e boronic acid synergy test, and the metallo-beta-lactamase Etest, had specificities of >90% for dete

133 the presence of high levels of contaminating beta-lactamases expressed by other clinically prevalent

134 Some members of the class A beta-lactamase family are capable of conferring resistan

135 ts reveal that the robustness of the overall beta-lactamase fold coupled with the plasticity of an ac

136 esistance genes, including extended spectrum beta-lactamases, for which therapeutic options are scarc

137 sted against two clinically relevant class C beta-lactamases from Enterobacter spp. and Pseudomonas a

138 (serine beta-lactamase) but not L1 (metallo beta-lactamase) from the extensively drug resistant huma

139 mating a lower bound of evidence for metallo-beta-lactamase functionality but not an upper bound.

140 that ancestral proteins may have had metallo-beta-lactamase functionality with variation in sequence

141 e models conform to our criteria for metallo-beta-lactamase functionality, suggesting that the ancest

142 Finally, we used our beta-lactamase FunFams and ASSP profiles to detect 4 nov

143 SrgE with beta-lactamase fused to residue 40, 100, 150, or 300 was

144 translocated into host cells, but SrgE with beta-lactamase fused to residue 400 or 488 was not expre

145 ila producing a fusion protein consisting of beta-lactamase fused to the T4SS-translocated effector R

146 erexpression of a gene island-borne putative beta-lactamase gene was observed following piperacillin-

147 ion surrounding the active site of the TEM-1 beta-lactamase gene.

148 gene (bla CMY-42) and two extended-spectrum beta-lactamase genes (bla CTX-M-15 and bla SHV-12).

149 n gram-negative bacteria (GNB) are numerous; beta-lactamase genes carried on mobile genetic elements

150 -magnitude reductions in effluent-associated beta-lactamase genes in effluent-saturated soils, sugges

151 s were molecularly characterized to identify beta-lactamase genes.

152 beta-lactams have led to the conclusion that beta-lactamases have evolved from a DD-peptidase ancesto

153 mpicillin, and cefazolin, are protected from beta-lactamase hydrolysis via the formation of unique io

154 ormational properties of the Bacillus cereus beta-lactamase II in the presence of chemical denaturant

155 lass of inhibitors for NDM-1 and two related beta-lactamases, IMP-1 and VIM-2, was identified.

156 ole of WhiB4 in coordinating the activity of beta-lactamase in a redox-dependent manner to tolerate A

157 the nonoutbreak spread of New Delhi metallo-beta-lactamase in diverse Enterobacteriaceae species.

158 TEM-1 is a prevalent plasmid-encoded beta-lactamase in Gram-negative bacteria that efficientl

159 bolites were shown to activate expression of beta-lactamase in the absence of any beta-lactam antibio

160 tection of carbapenemases, including metallo-beta-lactamases in active bacterial pathogens.

161 pectrometry (LC-MS/MS) was applied to detect beta-lactamases in clinical Acinetobacter baumannii isol

162 ced holomycin also strongly inhibits metallo-beta-lactamases in vitro, major contributors to clinical

163 SME type), 40 isolates that produced metallo-beta-lactamases (including NDM-1, GIM-1, SPM-1, IMP-1, -

164 nalogues able to inhibit clinically-relevant beta-lactamases, including AmpC, Extended-Spectrum BLs (

165 occus aureus and Escherichia coli expressing beta-lactamases, infection was cleared when treated with

166 with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem

167 c inhibitors, such as the derivatives of the beta-lactamase inhibitor avibactam, are closer to the cl

168 Resistance to the novel beta-lactam/beta-lactamase inhibitor combination ceftazidime-avibact

169 ndings should not be extended to beta-lactam/beta-lactamase inhibitor combinations in development, as

170 y with respect to empirical therapy with new beta-lactamase inhibitor combinations such as ceftazidim

171 am are 2 new second-generation cephalosporin/beta-lactamase inhibitor combinations.

172 s for the use of next-generation beta-lactam-beta-lactamase inhibitor combinations.

173 d in the final deprotection/isolation of the beta-lactamase inhibitor MK-7655 as a part of its manufa

174 antibacterial combination consisting of the beta-lactamase inhibitor tazobactam and a fourth-generat

175 lass, such as meropenem, with clavulanate, a beta-lactamase inhibitor, are being evaluated for the tr

176 ycobactericidal activity in combination with beta-lactamase inhibitor, clavulanate (Clav).

177 dependent upon or enhanced by clavulanate, a beta-lactamase inhibitor.

178 s and are unaffected by clinically available beta-lactamase inhibitors (betaLIs).

179 CI, 1.15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.2

180 initiated to discover a new series of serine beta-lactamase inhibitors containing a boronic acid phar

181 tive drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstre

182 Although several new beta-lactamase inhibitors have been approved or are in c

183 ms, whereas newer drug classes include novel beta-lactamase inhibitors in combination with new or app

184 characterization of expanded-spectrum serine beta-lactamase inhibitors that potently inhibit clinical

185 A multiligand set of boronic acid (BA) beta-lactamase inhibitors was obtained using covalent mo

186 , and combinations of penicillins, including beta-lactamase inhibitors) and two had a known interacti

187 including green fluorescent proteins (GFPs), beta-lactamase inhibitors, and nuclear receptors, and we

188 ere to guide the creation of two novel short beta-lactamase inhibitors, here named dBLIP-1 and -2, wi

189 and avibactam are clinically deployed serine beta-lactamase inhibitors, important as a defence agains

190 ephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains a

191 ztreonam-like beta-lactams plus nonclassical beta-lactamase inhibitors, particularly avibactam-like a

192 present one of the most promising classes of beta-lactamase inhibitors.

193 lactam antibiotics in a manner distinct from beta-lactamase inhibitors.

194 mechanism distinct from that of traditional beta-lactamase inhibitors.

195 in real time the catalytic activity of TEM1-beta-lactamase inside living cells and compared the valu

196 In particular, derepression of the AmpC beta-lactamase is a common mechanism of beta-lactam resi

197 Inducible expression of chromosomal AmpC beta-lactamase is a major cause of beta-lactam antibioti

198 The designed metallo-beta-lactamase is functional in the Escherichia coli per

199 The catalytic mechanism of class A beta-lactamases is often debated due in part to the larg

200 ic acid (BZB), a nanomolar inhibitor of AmpC beta-lactamase (K i = 27 nM), we have identified and cha

201 Metallo-beta-lactamases (MbetaLs) are the main mechanism of resi

202 a major health threat by expressing metallo-beta-lactamases (MbetaLs), enzymes able to hydrolyse the

203 is a mono-iron binding member of the metallo-beta-lactamase (MBL) fold superfamily.

204 g a motif related to the prokaryotic metallo-beta-lactamase (MBL) fold.

205 d VIM-2 and IMP-18, and 7 carried no metallo-beta-lactamase (MBL) gene.

206 Metallo-beta-lactamase (MBL) inhibitors can restore the function

207 The metallo-beta-lactamase (MBL) is a candidate protein family that

208 y the emergence and global spread of metallo-beta-lactamase (MBL) mediated resistance, specifically N

209 KPC- and OXA-type carbapenemases and metallo-beta-lactamases (MBL).

210 Metallo-beta-lactamases (MBLs) hydrolyze almost all beta-lactam

211 Development of metallo-beta-lactamases (MBLs) inhibitors has proven challenging

212 beta-lactam antibiotics mediated by metallo-beta-lactamases (MBLs) is a growing problem.

213 ces (PADs) that can test for the presence of beta-lactamase-mediated resistance.

214 vealed that it shared sequence homology with beta-lactamase/metallo-beta-lactamases (enzymes that pro

215 High activity against extended-spectrum beta-lactamase, methicillin-resistant S. aureus, and car

216 ssive temperatures using a library of random beta-lactamase mutants containing these noncanonical ami

217 iaceae (CRE) producing the New Delhi metallo-beta-lactamase (NDM) are rare in the United States, but

218 New Delhi metallo-beta-lactamase (NDM) represents a serious challenge for

219 The New Delhi metallo-beta-lactamase (NDM-1) is involved in the emerging antib

220 However, the emergence and spread of beta-lactamase-negative ampicillin-resistant strains in

221 to discriminate between clinically-relevant beta-lactamases on the basis of their inhibition profile

222 Previous use of beta-lactam/beta-lactamase or carbapenems and recent hospitalization

223 49 previously unrecognized extended-spectrum beta-lactamase or plasmid AmpC targets were detected and

224 Furthermore, in contrast to metallo-beta-lactamases or Klebsiella pneumoniae carbapenemases

225 minate between ESBL and non-ESBL TEM and SHV beta-lactamases or to specify CTX-M genes by group.

226 development of new inhibitors of the class D beta-lactamase oxacillinase-48 (OXA-48) through surface

227 ized 10-site library (1,536 variants) of P99 beta-lactamase (P99betaL), a component of ADEPT cancer t

228 All isolates were beta-lactamase positive and were resistant to penicillin

229 superior activity against extended spectrum beta lactamase producers, despite diminished activity ag

230 , 27% Pseudomonas, and 10% extended-spectrum beta-lactamase-producing bacteria, without evidence of t

231 chment on the detection of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) in

232 s) were rectal carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), co

233 m infections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E).

234 ntestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) an

235 Extended-spectrum beta-lactamase-producing Enterobacteriaceae are difficul

236 y and specificity of prior extended-spectrum beta-lactamase-producing Enterobacteriaceae colonization

237 dependent risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae colonization

238 e surveillance culture for extended-spectrum beta-lactamase-producing Enterobacteriaceae detection wa

239 Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae digestive co

240 f the digestive tract with extended-spectrum beta-lactamase-producing Enterobacteriaceae during ICU-h

241 isolation of at least one extended-spectrum beta-lactamase-producing Enterobacteriaceae from rectal

242 acquired colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in previousl

243 more likely to develop an extended-spectrum beta-lactamase-producing Enterobacteriaceae infection (r

244 tion to predict subsequent extended-spectrum beta-lactamase-producing Enterobacteriaceae infection we

245 nization as a predictor of extended-spectrum beta-lactamase-producing Enterobacteriaceae involvement

246 Studies reporting extended-spectrum beta-lactamase-producing Enterobacteriaceae outbreaks or

247 uble disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteriaceae phenotypic c

248 eria, infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae predominated

249 (6.8%) were colonized with extended-spectrum beta-lactamase-producing Enterobacteriaceae prior to the

250 he ICU acquisition rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae ranged from

251 interest of screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae rectal carri

252 cantly higher frequency of extended-spectrum beta-lactamase-producing Enterobacteriaceae subsequent i

253 ence for human exposure to extended-spectrum beta-lactamase-producing Enterobacteriaceae, methicillin

254 ed as being colonized with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

255 ciated pneumonia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae; of whom, 17

256 colonized or infected with extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC).

257 erminants of the spread of extended-spectrum beta-lactamase-producing Escherichia coli (ESBLEC) in th

258 occus aureus) and ESBL-EC (extended-spectrum beta-lactamase-producing Escherichia coli) results in a

259 tant Escherichia coli, and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Salmo

260 postintervention cases of extended-spectrum beta-lactamase-producing organisms (P = 0.049) but not o

261 s for infections caused by extended-spectrum beta-lactamase-producing organisms, AmpC beta-lactamase-

262 rum beta-lactamase-producing organisms, AmpC beta-lactamase-producing organisms, carbapenem-resistant

263 with a high prevalence of extended-spectrum beta-lactamase-producing organisms.

264 a-lactams, cephalosporins (extended-spectrum beta-lactamase-producing type SHV-12), and quinolones (p

265 illin-resistant S. aureus, extended-spectrum beta-lactamase-producing, and carbapenem-resistant Enter

266 Combined extended-spectrum beta-lactamase production (blaTEM-1 gene) and azithromyc

267 lin zone edge and nitrocefin-based tests for beta-lactamase production in Staphylococcus aureus were

268 beta-lactamase production is the predominant mechanism o

269 Artemis is a member of the metallo-beta-lactamase protein family of nucleases.

270 The correlation of the detection of beta-lactamase proteins (rather than PCR detection of th

271 oxicants is the antioxidant response element beta lactamase reporter gene assay (ARE-bla), which iden

272 imited proteolysis, one-dimensional NMR, and beta-lactamase reporter assays on eukaryotic cells, we s

273 Beta-lactamases represent the main bacterial mechanism o

274 red 2 drug groups having known interactions (beta-lactamase-resistant penicillins [dicloxacillin] and

275 as first evaluated using a recombinant TEM-1 beta-lactamase, resulting in 68% of the amino acid seque

276 his marks the first preparation of a metallo-beta-lactamase selectively substituted with a paramagnet

277 richia coli cells carrying New Delhi metallo-beta-lactamase subclass 1 (NDM-1) can be monitored in re

278 ging to both metallo (MBL)- and serine (SBL)-beta-lactamase subfamilies.

279 tructures of three fragment complexes of the beta-lactamase substrate cephalothin were determined by

280 wever, avibactam does not inactivate metallo-beta-lactamases such as New Delhi metallo-beta-lactamase

281 it 11 (IntS11), which belongs to the metallo-beta-lactamase superfamily and is a paralog of CPSF-73,

282 and Salmonella enterica subsp. arizonae The beta-lactamase TEM-1 reporter system showed that SeoC is

283 he penicillin disk diffusion test, and three beta-lactamase tests, including the cefoxitin-induced ni

284 CphA is a Zn(2+)-dependent metallo-beta-lactamase that efficiently hydrolyzes only carbapen

285 niae carbapenemase (KPC) production or other beta-lactamases that hydrolyze carbapenems.

286 ch allows us to propose a grouping of serine beta-lactamases that more consistently captures and rati

287 ring that is hydrolyzed by the enzyme BlaC (beta-lactamase) that is naturally expressed by M. tuberc

288 Among the reads characterized as beta-lactamases, the carbapenemase blaOXA was dominant i

289 Although they are grouped in class A beta-lactamases, the CTX-M family possesses low sequence

290 We focused on Class A beta-lactamases, the most highly populated and clinicall

291 Although developed for the serine beta-lactamases they could be used to classify and analy

292 nslocation reporter was engineered by fusing beta-lactamase to the N terminus of TeNT [betalac-TeNT(R

293 site similarities, why was it necessary for beta-lactamases to evolve at all?

294 gene encoding the emerging New Delhi metallo-beta-lactamase, using label-free electrochemical impedan

295 We assayed a TEM-1 beta-lactamase variant and levoglucosan kinase (LGK) usi

296 e (KPC), and Verona integron-encoded metallo-beta-lactamase (VIM) were the most common carbapenemases

297 relevant MBL Verona integron-encoded metallo-beta-lactamase (VIM-2).

298 ined the plasticity of the interface of TEM1 beta-lactamase with its protein inhibitor BLIP by low-st

299 Insidious coproduction of metallo-beta-lactamase with KPC-type carbapenemase has implicati

300 enzyme complex of perdeuterated E166A Toho-1 beta-lactamase with the antibiotic cefotaxime.